Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma

Key Points Anti-sclerostin treatment increases bone mass and fracture resistance in MM Anti-sclerostin in combination with zoledronic acid is superior to zoledronic acid alone in increasing fracture resistance.